FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2783131675> ?p ?o ?g. }

• W2783131675 abstract "The aim was to analyze characteristics that predict remission induction and subsequent loss of remission in patients with moderately active rheumatoid arthritis (RA) who received full-dose combination etanercept plus methotrexate induction therapy followed by reduced-dose etanercept or etanercept withdrawal. Patients with Disease Activity Score based on 28-joint count (DAS28) >3.2 and ≤5.1 received open-label etanercept 50 mg once weekly (QW) plus methotrexate for 36 weeks. Those who achieved DAS28 low disease activity by 36 weeks were randomized to double-blind treatment with etanercept 50 mg or 25 mg QW plus methotrexate or placebo plus methotrexate for 52 weeks. All analyses were adjusted for the continuous baseline variables of their respective remission outcomes. Younger age, body mass index (BMI) <30 kg/m2, and lower Health Assessment Questionnaire (HAQ) score at baseline were significant predictors of week-36 remission (P < 0.05) based on DAS28, Simplified Disease Activity Index (SDAI), and Clinical Disease Activity Index (CDAI). Baseline DAS28, SDAI, and CDAI were significantly predictive of all three remission endpoints (P < 0.05). For all three treatments, the strongest predictors of loss of DAS28 remission included failure to achieve sustained remission (DAS28 < 2.6 at weeks 12, 20, 28, and 36) with induction therapy, higher DAS28/SDAI/CDAI at randomization and at 1 month, increase in DAS28/SDAI/CDAI at 1 month, and increase in DAS28/CDAI/SDAI components and patient-reported outcomes (PROs) at 1 month. With the exception of not achieving sustained remission, very similar significant predictors were observed for loss of SDAI and CDAI remission. These findings suggest that patients with moderately active RA who are younger and have lower BMI, lower HAQ, and lower disease activity at baseline are most likely to achieve remission when receiving combination etanercept and methotrexate induction therapy. In addition, patients who fail to achieve sustained remission with induction therapy and those with worse disease activity and PROs at early time points after initiating maintenance therapy with a full-dose or reduced-dose etanercept-methotrexate regimen or methotrexate monotherapy are most likely to lose remission across all treatment arms. These findings may help guide clinicians’ decision-making as they treat patients to remission and beyond. ClinicalTrials.gov, NCT00565409 . Registered on 28 November 2007" @default.
• W2783131675 created "2018-01-26" @default.
• W2783131675 creator A5024697092 @default.
• W2783131675 creator A5041835212 @default.
• W2783131675 creator A5061716516 @default.
• W2783131675 creator A5082474412 @default.
• W2783131675 creator A5090753435 @default.
• W2783131675 date "2018-01-16" @default.
• W2783131675 modified "2023-10-17" @default.
• W2783131675 title "Predictors of remission with etanercept-methotrexate induction therapy and loss of remission with etanercept maintenance, reduction, or withdrawal in moderately active rheumatoid arthritis: results of the PRESERVE trial" @default.
• W2783131675 cites W2000333164 @default.
• W2783131675 cites W2031388906 @default.
• W2783131675 cites W2054789510 @default.
• W2783131675 cites W2069836482 @default.
• W2783131675 cites W2099321660 @default.
• W2783131675 cites W2099334955 @default.
• W2783131675 cites W2113476392 @default.
• W2783131675 cites W2114909821 @default.
• W2783131675 cites W2120393706 @default.
• W2783131675 cites W2140731614 @default.
• W2783131675 cites W2142004396 @default.
• W2783131675 cites W2148357532 @default.
• W2783131675 cites W2152553239 @default.
• W2783131675 cites W2155109530 @default.
• W2783131675 cites W2159331314 @default.
• W2783131675 cites W2169713004 @default.
• W2783131675 cites W2727546362 @default.
• W2783131675 cites W4210768724 @default.
• W2783131675 cites W4249063051 @default.
• W2783131675 doi "https://doi.org/10.1186/s13075-017-1484-9" @default.
• W2783131675 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/5771183" @default.
• W2783131675 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/29338762" @default.
• W2783131675 hasPublicationYear "2018" @default.
• W2783131675 type Work @default.
• W2783131675 sameAs 2783131675 @default.
• W2783131675 citedByCount "28" @default.
• W2783131675 countsByYear W27831316752018 @default.
• W2783131675 countsByYear W27831316752019 @default.
• W2783131675 countsByYear W27831316752020 @default.
• W2783131675 countsByYear W27831316752021 @default.
• W2783131675 countsByYear W27831316752022 @default.
• W2783131675 countsByYear W27831316752023 @default.
• W2783131675 crossrefType "journal-article" @default.
• W2783131675 hasAuthorship W2783131675A5024697092 @default.
• W2783131675 hasAuthorship W2783131675A5041835212 @default.
• W2783131675 hasAuthorship W2783131675A5061716516 @default.
• W2783131675 hasAuthorship W2783131675A5082474412 @default.
• W2783131675 hasAuthorship W2783131675A5090753435 @default.
• W2783131675 hasBestOaLocation W27831316751 @default.
• W2783131675 hasConcept C126322002 @default.
• W2783131675 hasConcept C142724271 @default.
• W2783131675 hasConcept C1862650 @default.
• W2783131675 hasConcept C198451711 @default.
• W2783131675 hasConcept C204787440 @default.
• W2783131675 hasConcept C27081682 @default.
• W2783131675 hasConcept C2777226972 @default.
• W2783131675 hasConcept C2777575956 @default.
• W2783131675 hasConcept C2781059491 @default.
• W2783131675 hasConcept C71924100 @default.
• W2783131675 hasConceptScore W2783131675C126322002 @default.
• W2783131675 hasConceptScore W2783131675C142724271 @default.
• W2783131675 hasConceptScore W2783131675C1862650 @default.
• W2783131675 hasConceptScore W2783131675C198451711 @default.
• W2783131675 hasConceptScore W2783131675C204787440 @default.
• W2783131675 hasConceptScore W2783131675C27081682 @default.
• W2783131675 hasConceptScore W2783131675C2777226972 @default.
• W2783131675 hasConceptScore W2783131675C2777575956 @default.
• W2783131675 hasConceptScore W2783131675C2781059491 @default.
• W2783131675 hasConceptScore W2783131675C71924100 @default.
• W2783131675 hasFunder F4320307765 @default.
• W2783131675 hasIssue "1" @default.
• W2783131675 hasLocation W27831316751 @default.
• W2783131675 hasLocation W27831316752 @default.
• W2783131675 hasLocation W27831316753 @default.
• W2783131675 hasLocation W27831316754 @default.
• W2783131675 hasLocation W27831316755 @default.
• W2783131675 hasOpenAccess W2783131675 @default.
• W2783131675 hasPrimaryLocation W27831316751 @default.
• W2783131675 hasRelatedWork W2054504654 @default.
• W2783131675 hasRelatedWork W2061873374 @default.
• W2783131675 hasRelatedWork W2090686119 @default.
• W2783131675 hasRelatedWork W2098767548 @default.
• W2783131675 hasRelatedWork W2145306293 @default.
• W2783131675 hasRelatedWork W2361180466 @default.
• W2783131675 hasRelatedWork W2397416720 @default.
• W2783131675 hasRelatedWork W2783466784 @default.
• W2783131675 hasRelatedWork W2922478221 @default.
• W2783131675 hasRelatedWork W2011109976 @default.
• W2783131675 hasVolume "20" @default.
• W2783131675 isParatext "false" @default.
• W2783131675 isRetracted "false" @default.
• W2783131675 magId "2783131675" @default.
• W2783131675 workType "article" @default.